# US 11,896,579 B2 · Combination drug

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,579 B2
- Document ID: US11896579B2
- Status: Granted
- Kind: B2
- Application number: 17/358,933
- Filed: 2021-06-25
- Published: 2021-10-21
- Granted: 2024-02-13
- Earliest claimed: 2015-01-16
- Assignees: Chugai Seiyaku Kabushiki Kaisha
- Applicants: Chugai Seiyaku Kabushiki Kaisha
- Inventors: Hiroshi Sakamoto; Toshiyuki Tsukaguchi
- Web page: https://patentgrep.com/patent/US11896579B2

## CPC

- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5355: Non-condensed oxazines and containing further heterocyclic rings
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a drug that is for treating or preventing cancer, that is effective in the treatment of cancer, and that comprises a combination of an ALK inhibitor and a VEGF inhibitor. The present invention also relates to a method for treating or preventing cancer and a method for inhibiting tumor growth.

## Claims

### Claim 1

A method of treating a cancer comprising: administering, in combination, an effective amount of ALK inhibitor and an effective amount of VEGF inhibitor to a subject in need thereof, wherein the ALK inhibitor is alectinib or a salt thereof and the VEGF inhibitor is bevacizumab.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the ALK inhibitor and the VEGF inhibitor are administered in separate dosage forms.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the ALK inhibitor and the VEGF inhibitor are administered simultaneously.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the cancer is selected from the group consisting of non-Hodgkin's lymphoma, neuroblastoma, inflammatory myofibroblastic tumor, renal cancer, and lung cancer.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the cancer is positive for an ALK fusion gene.

### Claim 6

A method of suppressing growth of a tumor comprising: administering, in combination, an effective amount of ALK inhibitor and an effective amount of VEGF inhibitor to a subject in need thereof, wherein the ALK inhibitor is alectinib or a salt thereof and the VEGF inhibitor is bevacizumab.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the ALK inhibitor and the VEGF inhibitor are administered in separate dosage forms.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the ALK inhibitor and the VEGF inhibitor are administered simultaneously.

### Claim 9 (depends on 6)

The method according to claim 6, wherein the tumor is selected from the group consisting of non-Hodgkin's lymphoma, neuroblastoma, inflammatory myofibroblastic tumor, renal cancer, and lung cancer.

### Claim 10 (depends on 6)

The method according to claim 6, wherein the tumor has an ALK fusion gene.

### Claim 11 (depends on 6)

The method according to claim 6, wherein the alectinib or a salt thereof is administered at a dose of 20 mg, 40 mg, 60 mg, 80 mg, 120 mg, 160 mg, 220 mg, 240 mg, 300 mg, 460 mg, 600 mg, 760 mg or 900 mg calculated as a free form twice a day.

### Claim 12 (depends on 6)

The method according to claim 6, wherein the bevacizumab is administered at 1 μg/kg to 50 mg/kg.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the bevacizumab is administered at 5 mg/kg, 7.5 mg/kg, 10 mg/kg or 15 mg/kg.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the bevacizumab is administered once a week, once every two weeks, or once every three weeks.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the alectinib or a salt thereof is administered at a dose of 20 mg, 40 mg, 60 mg, 80 mg, 120 mg, 160 mg, 220 mg, 240 mg, 300 mg, 460 mg, 600 mg, 760 mg or 900 mg calculated as a free form twice a day.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the bevacizumab is administered at 1 μg/kg to 50 mg/kg.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the bevacizumab is administered at 5 mg/kg, 7.5 mg/kg, 10 mg/kg or 15 mg/kg.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the bevacizumab is administered once a week, once every two weeks, or once every three weeks.

### Claim 19 (depends on 2)

The method according to claim 2, wherein the ALK inhibitor and the VEGF inhibitor are administered sequentially.

### Claim 20 (depends on 7)

The method according to claim 7, wherein the ALK inhibitor and the VEGF inhibitor are administered sequentially.